Leap Therapeutics, Inc.

Leap Therapeutics, Inc. is currently considered overvalued due to unfavorable financial metrics and peer comparisons, with a year-to-date return of -89.25% compared to the S&P 500's 2.44%.

As of April 21, 2025, the market trend is mildly bearish, indicated by bearish daily moving averages and Bollinger Bands, despite some mixed signals from the MACD and Dow Theory.

As of March 2022, the management team of Leap Therapeutics, Inc. includes Dr. Christopher Mirabelli (Chairman), Mr. Douglas Onsi (CEO), and several independent directors: Dr. Thomas Dietz, Dr. Monica Bertagnolli, Dr. James Cavanaugh, Dr. William Li, and Dr. Joseph Loscalzo. This team oversees the company's governance and strategic direction.

Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing cancer therapies that inhibit tumor-promoting pathways and activate the immune system. It operates as a micro-cap company with a market cap of $15.61 million and reported a net profit loss of $15 million as of March 2025.

As of Jun 18, Leap Therapeutics, Inc. has a market capitalization of 15.61 million, with net sales of 0.00 million and a net profit of -69.18 million over the last four quarters. The company reported shareholder's funds of 35.05 million and total assets of 49.12 million as of Dec 24.